

## Health Technology Briefing January 2023

### Dabrafenib with trametinib for treating metastatic or unresectable BRAF V600 mutation-positive melanoma in adolescents

Company/Developer

Novartis Pharmaceuticals UK Ltd

New Active Substance

Significant Licence Extension (SLE)

NIHRIO ID: 34836

NICE TSID: 11838

UKPS ID: 666019

#### Licensing and Market Availability Plans

Currently in phase I/II clinical trials.

#### Summary

Dabrafenib in combination with trametinib is currently in clinical development for the treatment of advanced BRAF V600 mutation-positive melanoma in adolescents. Melanoma is a type of skin cancer. Common signs include the appearance of a new mole or a change in an existing mole. This can happen anywhere on the body, but the most commonly affected areas are the back in men and the legs in women. It is caused by ultraviolet (UV) light damaging the DNA in skin cells. Despite being rare, melanoma is the most common cancer in children, often more common in adolescents aged 15 – 19 years. Patients who have unresectable or metastatic melanoma have had the cancer spread to distant parts of the body and it cannot be surgically removed. Current treatment options for unresectable or metastatic melanoma are recommended for use in adults, there is therefore need for effective treatment options for young adults.

Dabrafenib inhibits a protein called BRAF which prevents tumour cells from growing. Trametinib blocks the activation of BRAF thereby slowing down the growth and spread of the cancer. Dabrafenib in combination with trametinib has been approved for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Dabrafenib and trametinib are administered orally. If licensed, dabrafenib with trametinib will offer a novel treatment option for unresectable or metastatic BRAF V600 mutation-positive melanoma in adolescent patients.

## Proposed Indication

Treatment of advanced BRAF V600 mutation-positive solid tumours in adolescents.<sup>1,2</sup>

## Technology

### Description

Dabrafenib (Tafinlar, DRB436) is an inhibitor of rapidly accelerated fibrosarcoma (RAF) kinases. Oncogenic mutations in BRAF (B-Raf serine-threonine kinase) lead to constitutive activation of the RAS/RAF/MEK/ERK pathway. BRAF mutations have been identified at a high frequency in specific cancers, including approximately 50% of melanoma. Preclinical data generated in biochemical assays demonstrated that dabrafenib inhibits BRAF kinases with activating codon 600 mutations. Dabrafenib has demonstrated suppression of a downstream pharmacodynamic biomarker (phosphorylated ERK) and inhibited cell growth of BRAF V600 mutant melanoma cell lines, in vitro and in animal models.<sup>3</sup>

Trametinib (Mekinist, TMT212) is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2 activation and kinase activity. MEK proteins are components of the extracellular signal-related kinase (ERK) pathway. In melanoma and other cancers, this pathway is often activated by mutated forms of BRAF which activates MEK. Trametinib inhibits activation of MEK by BRAF and inhibits MEK kinase activity. Trametinib has been shown to inhibit growth of BRAF V600 mutant melanoma cell lines and demonstrates anti-tumour effects in BRAF V600 mutant melanoma animal models.<sup>4</sup>

Dabrafenib in combination with trametinib is currently in clinical development for treatment of advanced BRAF V600 mutation-positive solid tumours in adolescents. In the phase I/II clinical trials (NCT01677741, NCT02124772), dabrafenib was administered orally as a single dose on day 1 and twice daily from day 2 based on weight at the appropriate study dose level, and trametinib was administered orally at a dose of 0.0125 mg/kg/day, 0.025 mg/kg/day, 0.032 mg/kg/day, or 0.04 mg/kg/day once daily.<sup>1,2</sup>

### Key Innovation

Patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation have prolonged progression-free survival and overall survival when receiving treatment with BRAF inhibitors plus MEK inhibitors.<sup>5</sup> Survival data for various combination therapies shows promising survival gains compared with monotherapies. Dabrafenib plus trametinib is a new combination treatment that slows disease progression and improves quality of life in adults. Dabrafenib plus trametinib would be used in place of BRAF-inhibitor monotherapy as the standard of care in patients with BRAF mutation-positive diseases.<sup>6</sup> Dabrafenib in combination with trametinib has been shown to increase survival rates in approximately one third of patients who had unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.<sup>5</sup>

If licensed, dabrafenib in combination with trametinib will provide a novel treatment option for metastatic or unresectable BRAF V600 mutation-positive melanoma in adolescents.

### Regulatory & Development Status

Dabrafenib and trametinib are currently licensed in the UK for the following indications:<sup>3,4</sup>

- either as monotherapy or in combination for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

- in combination for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection
- in combination for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.

Dabrafenib in combination with trametinib is in phase II and III clinical development for multiple rare cancer indications such as:<sup>7</sup>

- differentiated thyroid cancer
- glioma
- non-small cell lung cancer
- ameloblastoma
- astrocytoma
- metastatic colorectal cancer

Dabrafenib in combination with trametinib has the following regulatory designations:<sup>8,9</sup>

- an orphan drug in the USA in 2012 for the treatment of Stage IIb through IV melanoma
- Breakthrough Therapy by the US FDA for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations in October 2017

## Patient Group

### Disease Area and Clinical Need

Melanoma is a type of skin cancer that can spread to other organs in the body. The most common sign of melanoma is the appearance of a new mole or a change in an existing mole. This can happen anywhere on the body, but the most commonly affected areas are the back in men and the legs in women. Most melanomas are caused by exposure to ultraviolet (UV) light from the sun. People mostly at risk of melanoma tend to have lots of moles or freckles, pale skin that burns easily, red or blonde hair, or have a family history of melanoma.<sup>10</sup> Stage IV melanoma has spread to distant parts of the body, such as distant lymph nodes or the liver, lung, brain, bone, or gastrointestinal tract, and is often referred to as metastatic melanoma.<sup>11</sup> Unresectable refers to cancers that are not capable of being surgically removed.<sup>12</sup> The BRAF gene makes a protein that helps regulate cell growth, and a mutation in it can result in uncontrolled cell growth. BRAF mutation melanoma can lead to the cancer growing at a faster rate.<sup>13</sup> The most commonly observed BRAF mutation is V600E which accounts for approximately 90% of the BRAF mutations that are seen in melanoma.<sup>3</sup>

Melanoma skin cancer is the 5th most common cancer in the UK, accounting for 4% of all new cancer cases (2016-2018).<sup>14</sup> Even though melanoma is rare, it is the most common skin cancer in children, and occurs more often in adolescents aged 15 to 19 years.<sup>15</sup> In the UK (2021), among young people aged 15-24, malignant melanoma was twice as frequent in females as it was in males. Melanoma accounted for 10% of all cancer registrations in this age group, and skin carcinomas for a further 5%.<sup>16</sup>

### Recommended Treatment Options

NICE currently recommends the following treatment options for metastatic or unresectable BRAF V600 mutation-positive melanoma for adults and the committee agreed that the following treatment should not differ for young people/adolescents:<sup>17,18</sup>

- Vemurafenib
- Encorafenib with binimetinib
- Cobimetinib with vemurafenib

- Dabrafenib with trametinib
- Nivolumab
- Talimogene laherparepvec

### Clinical Trial Information

<b>Trial</b>	<a href="#">NCT01677741</a> , EudraCT: <a href="#">2012-001499-12</a> , Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumours <b>Phase I/II:</b> Completed <b>Location(s):</b> 5 EU countries, UK, USA, Canada and other countries <b>Study completion date:</b> December 2020
<b>Trial Design</b>	Non-randomised, parallel assignment, open label
<b>Population</b>	N=85; aged 12 months to 17 years; subjects with recurrent disease, refractory disease, or progressive disease after having received at least one standard therapy for their disease; BRAF V600 mutation-positive tumour
<b>Intervention(s)</b>	Dabrafenib (oral) administered as a single dose on day 1 and twice daily from day 2, based on weight at the appropriate study dose level
<b>Comparator(s)</b>	No comparator
<b>Outcome(s)</b>	Primary outcome measures: <ul style="list-style-type: none"> <li>• Incidence of treatment emergent adverse events (AEs) in Part 1 (dose escalation) [time frame: from study treatment start date till 28 days safety follow-up, assessed up to approximately 90 months]</li> <li>• Maximum concentration (C<sub>max</sub>) of Dabrafenib [time frame: week 1 say 1, week 3 day 15]</li> <li>• Area under the concentration-time curve over the dosing interval (AUC(0-τ)) and AUC from zero to infinity (AUC(0-inf)) of Dabrafenib (time frame: week 1 day 1)</li> </ul> See trial record for full list of other outcomes.
<b>Results (efficacy)</b>	See trial record
<b>Results (safety)</b>	See trial record

### Clinical Trial Information

<b>Trial</b>	<a href="#">NCT02124772</a> , EudraCT: <a href="#">2013-003596-35</a> , An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harbouring V600 Mutations <b>Phase I/II:</b> Completed <b>Location(s):</b> France, UK, USA, Canada and Australia <b>Study completion date:</b> December 2020
--------------	---

<b>Trial Design</b>	Non-randomised, parallel assignment, open label
<b>Population</b>	N=139; aged 1 month to 17 years; subjects with a disease that is relapsed/refractory to all potentially curative standard treatment regimens or must have a current disease for which there is no known curative therapy, or therapy proven to prolong survival with an acceptable quality of life; BRAF V600 mutant tumours
<b>Intervention(s)</b>	<ul style="list-style-type: none"> <li>Trametinib (oral) administered once daily at a dose of 0.0125 mg/kg/day, 0.025 mg/kg/day, 0.032 mg/kg/day or 0.04 mg/kg/day</li> <li>Dabrafenib (oral) administered twice daily. The daily dose was divided into two equal doses</li> </ul>
<b>Comparator(s)</b>	No comparator
<b>Outcome(s)</b>	<p>Primary outcome measures:</p> <ul style="list-style-type: none"> <li>Incidence of treatment emergent adverse events in subjects treated with trametinib monotherapy [time frame: from the day of the first dose of trametinib up to 30 days after the last dose, up to maximum duration of 64 months]</li> <li>Average steady state plasma concentration (C<sub>avg</sub>) of trametinib when administered alone (monotherapy) [time frame: pre dose, 1, 2, 4, 7, 10 and 24 hours post trametinib dose on Cycle 1 Day 15. The duration of 1 cycle was 28 days]</li> </ul> <p>See trial record for full list of other outcomes.</p>
<b>Results (efficacy)</b>	See trial record
<b>Results (safety)</b>	See trial record

### Estimated Cost

Dabrafenib is already marketed in the UK; a pack of 28 x 50mg capsules costs £933.33 and a pack of 28 x 75mg capsules costs £1,400.<sup>19</sup>

Trametinib is already marketed in the UK; a pack of 7 x 0.5mg tablets costs £280, a pack of 30 x 0.5mg tablets costs £1,200, a pack of 7 x 2mg tablets costs £1,120 and a pack of 30 x 2mg tablets costs £4,800.<sup>20</sup>

### Relevant Guidance

#### NICE Guidance

- NICE technology appraisal. Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562). February 2019.
- NICE technology appraisal. Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414). October 2016.
- NICE technology appraisal. Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410). September 2016.
- NICE technology appraisal. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396). June 2016.
- NICE technology appraisal. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384). February 2016.

- NICE technology appraisal. Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma (TA269). January 2015.
- NICE guideline. Melanoma: assessment and management (NG14). July 2022.
- NICE quality standard. Skin cancer (QS130). September 2016.

#### NHS England (Policy/Commissioning) Guidance

- NHS England. 2013/14 NHS Standard Contract for Cancer: Chemotherapy (Adult). B15/S/a.
- NHS England. 2013/14 NHS Standard Contract for NHS Standard Service Specification Template for Cancer: Chemotherapy (Children, Teenagers and Young Adults). B15/S/b.
- NHS England. 2013/14 NHS Standard Contract for Cancer: Skin (Adult). A12/s/b

#### Other Guidance

- European Dermatology Forum (EDF), European Association of Dermato-Oncology (EADO) and European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline. 2019.<sup>21</sup>
- European Society for Medical Oncology (ESMO). Cutaneous Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2019.<sup>22</sup>
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma, Version 2. 2019.<sup>23</sup>
- American Academy of Dermatology (ADD). ADD clinical practice guideline: Guidelines of care for the management of primary cutaneous melanoma. 2018.<sup>24</sup>

### Additional Information

### References

- 1 ClinicalTrials.gov. *An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations*. Trial ID: NCT02124772. 2014. Status: Completed. Available from: <https://clinicaltrials.gov/ct2/show/NCT02124772> [Accessed 14th October 2022].
- 2 ClinicalTrials.gov. *Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors*. Trial ID: NCT01677741. 2021. Status: Completed. Available from: <https://clinicaltrials.gov/ct2/show/NCT01677741> [Accessed 14th October 2021].
- 3 Electronic Medicines Compendium (EMC). *Tafinlar 50 mg hard capsules*. 2022. Available from: <https://www.medicines.org.uk/emc/product/5190/smpc> [Accessed 14th October 2022].

- 4 Electronic Medicines Compendium (EMC). *Mekinist 2 mg film-coated tablets*. 2022. Available from: <https://www.medicines.org.uk/emc/product/5072/smpc> [Accessed 14th October 2022].
- 5 Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. *N Engl J Med*. 2019;381(7):626-36. Available from: <https://doi.org/10.1056/NEJMoa1904059>.
- 6 National Institute for Health and Care Excellence (NICE). *Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma* 2016. Available from: <https://www.nice.org.uk/guidance/ta396/resources/trametinib-in-combination-with-dabrafenib-for-treating-unresectable-or-metastatic-melanoma-pdf-82602913532101> [Accessed 14th October 2022].
- 7 ClinicalTrials.gov. *Search: dabrafenib AND trametinib AND Novartis | Recruiting, Not yet recruiting, Active, not recruiting, Completed, Enrolling by invitation, Unknown status Studies | Phase 2, 3*. 2022. Available from: <https://www.clinicaltrials.gov/ct2/results?cond=&term=dabrafenib+AND+trametinib+AND+Novartis&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=d&recrs=e&recrs=f&recrs=m&phase=1&phase=2> [Accessed 14th October 2022].
- 8 U.S. Food & Drug Association (FDA). *Search Orphan Drug Designations and Approvals: trametinib and dabrafenib*. 2012. Available from: <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=376812> [Accessed 14th October 2022].
- 9 Onco Americas. *Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma*. Available from: <https://www.oncoamericas.com/en/novartis-receives-fda-approval-of-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/> [Accessed 14th October 2022].
- 10 NHS UK. *Skin cancer (melanoma)*. 2020. Available from: <https://www.nhs.uk/conditions/melanoma-skin-cancer/causes/> [Accessed 14th October 2022].
- 11 Cancer.net. *Melanoma: Types of Treatment*. Available from: <https://www.cancer.net/cancer-types/melanoma/types-treatment#:~:text=for%20certain%20patients.-,Advanced%20melanoma,to%20this%20as%20metastatic%20melanoma.>
- 12 Merriam Webster Dictionary. *Unresectable* Available from: <https://www.merriam-webster.com/dictionary/unresectable>.
- 13 Medical News Today. *What does a BRAF mutation in melanoma mean?* 2022. Available from: <https://www.medicalnewstoday.com/articles/braf-mutation-melanoma#what-is-a-braf-mutation> [Accessed 14th October 2022].
- 14 Cancer Research UK. 2018. Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer#heading-Zero> [Accessed 14th October 2022].
- 15 National Cancer Institute (NIH). *Childhood Melanoma Treatment (PDQ®)—Patient Version*. 2021. Available from: <https://www.cancer.gov/types/skin/patient/child-melanoma-treatment-pdq#:~:text=Melanoma%20is%20a%20rare%20form,other%20types%20of%20skin%20cancer.> [Accessed 14th October 2022].
- 16 Public Health England. *Children, teenagers and young adults UK cancer statistics report 2021*. 2021. Available from: <http://www.ncin.org.uk/view?rid=4272> [Accessed 14th October 2022].
- 17 National Institute for Health and Care Excellence (NICE). *Search: Advanced BRAF V600-Mutation melanoma*. Available from: <https://www.nice.org.uk/search?q=Advanced+BRAF+V600-Mutation+melanoma> [Accessed 14th October 2022].

- 18 National Institute for Health and Care Excellence (NICE). *Melanoma: assessment and management* 2015. Available from: <https://www.nice.org.uk/guidance/ng14/resources/melanoma-assessment-and-management-pdf-1837271430853> [Accessed 14th October 2022].
- 19 National Institute for Health and Care Excellence (NICE). *Dabrafenib - Medicinal forms*. Available from: <https://bnf.nice.org.uk/drugs/dabrafenib/medicinal-forms/> [Accessed 14th October 2022].
- 20 National Institute for Health and Care Excellence (NICE). *Trametinib - Medicinal forms*. Available from: <https://bnf.nice.org.uk/drugs/trametinib/medicinal-forms/> [Accessed 14th October 2022].
- 21 Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Bastholt L, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2019. *Eur J Cancer*. 2020;126:141-58. Available from: <https://doi.org/10.1016/j.ejca.2019.11.014>.
- 22 Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R, Keilholz U. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol*. 2019;30(12):1884-901. Available from: <https://doi.org/10.1093/annonc/mdz411>.
- 23 Coit DG, Thompson JA, Albertini MR, Barker C, Carson WE, Contreras C, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw*. 2019;17(4):367-402. Available from: <https://doi.org/10.6004/jnccn.2019.0018>.
- 24 Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, et al. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. 2019;80(1):208-50. Available from: <https://doi.org/10.1016/j.jaad.2018.08.055>.

**NB: This briefing presents independent research funded by the National Institute for Health and Care Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.**